13/05/2026
Polycystic O***y Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a landmark global consensus announced on May 12, 2026, in a study published by The Lancet.
While the condition itself remains unchanged, experts agreed the previous term “PCOS” was scientifically misleading because it incorrectly suggested the disorder was primarily about ovarian cysts, even though the “cysts” seen on ultrasound are actually immature egg follicles and may not even be present in many diagnosed individuals.
The new name better reflects the disorder’s complex, whole-body nature, highlighting its involvement in multiple hormonal systems, metabolic dysfunction, and reproductive health.
“Polyendocrine” refers to disruptions in hormones such as insulin and androgens, “Metabolic” acknowledges increased risks of weight gain, insulin resistance, type 2 diabetes, and cardiovascular disease, while “Ovarian” maintains recognition of its impact on ovulation, menstrual irregularities, and fertility.
Importantly, diagnostic criteria remain the same under the Rotterdam guidelines, and healthcare systems worldwide are expected to transition fully from PCOS to PMOS terminology by 2028.